欧盟罕用药政策的分析及其对我国的启示

发布时间：2018-04-06 04:32

本文选题：罕用药　切入点：罕见病　出处：《中国医院管理》2015年04期

【摘要】：目的通过分析欧盟及其成员国的罕用药相关政策,为我国罕用药及罕见病相关制度政策的制定提供参考。方法采用文献研究法对欧盟及其成员国法国、意大利、荷兰、英国的罕用药相关政策进行检索,并比较分析四国相关政策与制度的异同点。结果除欧盟统一的罕用药政策外,法国、意大利、荷兰以及英国均制定了相应的罕用药制度,设立罕见病治疗指导中心,有针对罕用药研发与价格制定的政策与措施,对于罕见病的治疗有相应的医疗保障制度,相应的政策制度较为完善。结论我国可借鉴其经验尽快制定罕见病的相关定义,建立罕见病中心,出台相应的研发激励与价格制定政策,并完善罕用药的报销与罕见病的医疗保障。
[Abstract]:Objective to provide a reference for the establishment of rare drug use and rare diseases in China by analyzing the relative policies of EU and its member states.Methods the relative policies of the EU and its member states, France, Italy, the Netherlands and the United Kingdom, were searched by literature research, and the similarities and differences between the four countries were compared and analyzed.Results in addition to the EU's unified policy on rare drug use, France, Italy, the Netherlands and the United Kingdom have all formulated corresponding rare drug use systems, setting up guidance centres for the treatment of rare diseases, with policies and measures aimed at the research and development and price of rare drugs.For the treatment of rare diseases, there is a corresponding medical security system, the corresponding policy system is relatively perfect.Conclusion our country can draw lessons from its experience to draw up the definition of rare disease, establish the center of rare disease, formulate the policy of R & D incentive and price, and perfect the reimbursement of rare medicine and the medical security of rare disease.
【作者单位】：中国药科大学国际医药商学院;
【分类号】：R95

【相似文献】